Other Abnormalities of Arginine Vasopressin Metabolism and Action

Published on 25/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2880 times

Chapter 553 Other Abnormalities of Arginine Vasopressin Metabolism and Action

Hyponatremia (serum sodium <130 mEq/L) in children is usually associated with severe systemic disorders and is most often due to intravascular volume depletion, excessive salt loss, or hypotonic fluid overload, especially in infants (Chapter 52). The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an uncommon cause of hyponatremia in children.

The initial approach to the patient with hyponatremia begins with determination of the volume status. A careful review of the patient’s history, physical examination, including changes in weight, and vital signs helps determine whether the patient is hypovolemic or hypervolemic. Supportive evidence includes laboratory data such as serum electrolytes, blood urea nitrogen, creatinine, uric acid, urine sodium, specific gravity, and osmolality (Chapter 52.3; Tables 553-1 and 553-2).

Table 553-1 DIFFERENTIAL DIAGNOSIS OF HYPONATREMIA

DISORDER INTRAVASCULAR VOLUME STATUS URINE SODIUM
Systemic dehydration Low Low
Decreased effective plasma volume Low Low
Primary salt loss (nonrenal) Low Low
Primary salt loss (renal) Low High
SIADH High High
Cerebral salt wasting Low Very high
Decreased free water clearance Normal or high Normal or high
Primary polydipsia Normal or high Normal
Runner’s hyponatremia Low Low
NSIAD High High
Pseudohyponatremia Normal Normal
Factitious hyponatremia Normal Normal

NSIAD, nephrogenic syndrome of inappropriate antidiuresis; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Causes of Hyponatremia

Pseudohyponatremia and Other Causes of Hyponatremia

Pseudohyponatremia can result from hypertriglyceridemia (Chapter 52). Elevated lipid levels result in a relative decrease in serum water content. As electrolytes are dissolved in the aqueous phase of the serum, they appear low when expressed as a fraction of the total serum volume. As a fraction of serum water, however, electrolyte content is normal. Modern laboratory methods that measure sodium concentration directly, independent of sample volume, do not cause this anomaly. Factitious hyponatremia can result from obtaining a blood sample proximal to the site of intravenous hypotonic fluid infusion.

Hyponatremia is also associated with hyperglycemia, which causes the influx of water into the intravascular space. Serum sodium decreases by 1.6 mEq/L for every 100 mg/dL increment in blood glucose >100 mg/dL. Glucose is not ordinarily an osmotically active agent and does not stimulate vasopressin release, probably because it can equilibrate freely across plasma membranes. In the presence of insulin deficiency and hyperglycemia, however, glucose acts as an osmotic agent, presumably because its normal intracellular access to osmosensor sites is prevented. Under these circumstances, an osmotic gradient exists, stimulating vasopressin release.

Treatment

Patients with systemic dehydration and hypovolemia should be rehydrated with salt-containing fluids such as normal saline or lactated Ringer solution. Because of activation of the renin-angiotensin-aldosterone system, the administered sodium is avidly conserved, and water diuresis quickly ensues as volume is restored and vasopressin concentrations decrease. Under these conditions, caution must be taken to prevent a too-rapid correction of hyponatremia, which can result in central pontine myelinolysis characterized by discrete regions of axonal demyelination and the potential for irreversible brain damage.

Hyponatremia due to a decrease in effective plasma volume caused by cardiac, hepatic, renal, or pulmonary dysfunction is more difficult to reverse. The most effective therapy is the least easily achieved: treatment of the underlying systemic disorder. For example, patients weaned from positive pressure ventilation undergo a prompt water diuresis and resolution of hyponatremia as cardiac output is restored and vasopressin concentrations decrease. AVP V2 receptor antagonists (aquaretics) have been developed. One of these, conivaptan, has been approved in the United States for the intravenous treatment of hospitalized adults with hyponatremia due to congestive heart failure. The safety and effectiveness of conivaptan in pediatric patients have not been studied.

Patients with hyponatremia due to primary salt loss require supplementation with sodium chloride and fluids. Initially, intravenous replacement of urine volume with fluid containing sodium chloride, 150-450 mEq/L depending on the degree of salt loss, may be necessary; oral salt supplementation may be required subsequently. This treatment contrasts with that of SIADH, in which water restriction without sodium supplementation is the mainstay.